Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CureVac ( (CVAC) ) has issued an announcement.
On May 23, 2025, CureVac N.V. announced the convening of its annual general meeting of shareholders scheduled for June 24, 2025, in Amsterdam. The meeting will address several key agenda items, including the adoption of the 2024 annual accounts, discussions on dividend policy, and the appointment and reappointment of board members. This meeting is significant for stakeholders as it outlines the company’s financial performance and strategic decisions, impacting its future operations and governance.
The most recent analyst rating on (CVAC) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on CureVac stock, see the CVAC Stock Forecast page.
Spark’s Take on CVAC Stock
According to Spark, TipRanks’ AI Analyst, CVAC is a Outperform.
CureVac’s stock score is driven by its strong financial performance and positive technical indicators. The company’s strategic collaborations and pipeline advancements add value, though operational restructuring and past financial volatility pose risks. The stock’s undervaluation enhances its attractiveness in the biotechnology sector.
To see Spark’s full report on CVAC stock, click here.
More about CureVac
CureVac N.V. is a biotechnology company based in Tübingen, Germany, specializing in the development of mRNA-based therapies. The company focuses on creating innovative treatments for various diseases, leveraging its expertise in mRNA technology.
Average Trading Volume: 641,478
Technical Sentiment Signal: Buy
Current Market Cap: $936.6M
Learn more about CVAC stock on TipRanks’ Stock Analysis page.